Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $206.67

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have been assigned an average rating of "Buy" from the eight research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $206.67.

A number of brokerages have weighed in on KRYS. Chardan Capital reaffirmed a "buy" rating and issued a $212.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup boosted their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company's stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new position in Krystal Biotech during the third quarter worth $40,000. Values First Advisors Inc. acquired a new position in shares of Krystal Biotech during the third quarter valued at about $53,000. GAMMA Investing LLC boosted its position in shares of Krystal Biotech by 184.8% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the company's stock worth $78,000 after purchasing an additional 279 shares in the last quarter. Huntington National Bank grew its stake in shares of Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company's stock valued at $104,000 after buying an additional 283 shares during the period. Finally, Blue Trust Inc. increased its position in Krystal Biotech by 242.4% in the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company's stock valued at $107,000 after buying an additional 412 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded down $0.25 during mid-day trading on Friday, reaching $154.81. The company had a trading volume of 151,918 shares, compared to its average volume of 215,160. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34. The business's 50-day simple moving average is $167.93 and its 200 day simple moving average is $181.02. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 87.46 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business's revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.67) EPS. On average, sell-side analysts anticipate that Krystal Biotech will post 3.03 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).